Please assess the completion status of the following clinical trial:

Trial Title: Normalization of Fasting Glucose and the Incidence of Restenosis After Peripheral Angioplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Both genders~2. Age between 30 and 75 years~3. Early type 2 diabetes, defined as FPG \>7.0 mmol/l or a PPG of 11.1 mmol/l or greater or a previous diagnosis of diabetes~4. Treatments accepted~   * Diet without pharmacological treatment~  * One or more oral antidiabetic drug (OAD: sulfonylureas, biguanides, meglitinides) at half-maximum dose or greater~  * Once daily insulin and OAD~5. Angiographic documentation of infrapopliteal arterial disease (stenosis \>70% or occlusion)~6. Critical limb ischemia (CLI) defined as~   * Persistent, recurring rest pain requiring analgesia and an ankle systolic pressure \<50 mm Hg and/or toe systolic pressure \<30 mm Hg or TcPO2 \<30 mm Hg~  * Ulceration, gangrene, or nonhealing wounds of the foot with ankle systolic pressure \<50 mm Hg or toe systolic pressure \<30 mm Hg or TcPO2 \<30 mm Hg~  * Fontaine stages III-IV and rutherford categories IV-VI~  * Lifestyle-limiting claudication defined as Rutherford category II to III associated with jeopardized single vessel runoff or complete trifurcation vessel occlusion.~7. Subject able to provide a signed and dated written informed consent~Exclusion Criteria:~1. Type 1 diabetes, defined as positivity for GAD antibodies measured by radiobinding assay~2. Unwilling to inject insulin or to perform a correct self monitoring of blood glucose~3. Acute limb ischemia~4. Buerger disease~5. Severe contrast allergy~6. Hypersensitivity to aspirin and/or clopidogrel~7. Systemic coagulopathy contraindicating antiaggregation therapy~8. Hypercoagulation disorder~9. Serum creatinine\>2.0 mg/dl at screening~10. Active liver disease, or ALT or AST \>2.5 times upper limit of normal at screening~11. Chronic or recurrent treatment with systemic corticosteroids~12. Malignant diseases~13. Psychiatric diseases which make participation impossible~14. Alcohol abuse

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- long-acting insulin plus analogues (Type: ACTIVE_COMPARATOR): three administrations of regular insulin or short acting insulin analogues before meals combined with long-acting insulin analogue glargine in the evening.
- long-acting insulin and oral agents (Type: ACTIVE_COMPARATOR): treatment will be once-daily long-acting insulin and oral antidiabetic agents

Based on this trial design, predict the completion outcome and termination type (if applicable).